Targeting Mitochondrial Fusion and Fission to Prevent Atherosclerosis: Getting the Balance Right
NCT ID: NCT03980548
Last Updated: 2019-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2018-10-10
2020-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
NCT05708547
Carotid Plaque Screening Trial in Smokers
NCT00548665
Molecular Mechanisms and Carotid Atherosclerosis
NCT03962686
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
NCT04027712
Lp-PLA2 and Coronary Atherosclerosis in Humans
NCT01557088
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis: Macrophages from femoral artery atherosclerotic plaques in patients with peripheral artery disease will display upregulation of mitochondrial fission proteins and features of pro-inflammatory activation.
Study 2 (white blood cell study): To investigate the changes in mitochondrial function and pro-inflammatory markers in white blood cells from patients with stable and unstable coronary artery didease (CAD).
Hypothesis: Monocytes from patients with unstable CAD will display upregulation of Drp1 and features of pro-inflammatory activation, mitochondrial fission, impaired mitochondrial respiratory function, and perturbed metabolism, when compared to monocytes from patients with stable CAD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CABG patients
CABG
Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
PAD patients
CABG
Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
Healthy volunteers
CABG
Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
Patients with CAD
CABG
Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CABG
Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
CABG patients
1. Patients aged ≥21 years old
2. Undergoing elective CABG with aortic valve surgery
PAD patients:
1. Patients aged ≥21 years old
2. Undergoing either elective surgical femoral or carotid endarterectomy
Study 2 (white blood cell study):
1\) Healthy volunteers aged ≥21 years old 2) Patients with stable CAD 3) Patients admitted with ACS treated by PCI in prior 24 hours.
\-
Exclusion Criteria
3. Cardiac arrest, Cardiogenic shock, Poor pre-morbid status, Pregnancy
21 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart Centre Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hector A. Cabrera-Fuentes
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHF/FG651P/2017
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2018/2497
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.